About Us
Established in 1992 and headquartered in Shenzhen, Joincare (Joincare Pharmaceutical Group Industry Co., Ltd) is an innovative scientific research-based integrated pharmaceutical group. The company has always adhered to the concept of scientific and technological innovation as the cornerstone, implementing a dual-driver strategy focused on innovative drugs and high-barrier complex formulation technology platforms. To date, it has developed four major platforms for the research and development of innovative high-barrier complex formulations. The group owns two major listed companies, Joincare and Livzon Pharmaceutical, as well as more than 20 major holding subsidiaries, with a workforce of over 14,000 employees. By the end of 2023, the company's total assets amounted to 36.358 billion yuan, with an operational revenue of 16.646 billion yuan."
View MoreNews
12
2024-12
Statement Regarding the Prevention of Illegal Activities Under the Guise of "Health Element"
At 8:40 am today, the group received a report that criminals were developing and operating the "Healthy Element" APP platform under the guise of the group, publishing and selling financial management products, and carrying out fraud. In response to this situation, the group makes the following solemn statement:
12
2024-12
Recently, we received notification from the National Pharmacopoeia Commission that the generic name application for Health Yuan's innovative influenza drug has been approved. It has been officially named "Mapaxisave" (the Chinese generic name for the raw material is "Mapaxisave", and the English name is "Pixavir Marboxil"; the Chinese generic name for the preparation is "Mapaxisave Capsules", and the English name is "Pixavir Marboxil Capsules").
10
2023-10
ESG performance is eye-catching, and Health Yuan's MSCI rating has jumped to AA.
Recently, MSCI, a leading international index provider, announced the results of its 2023 ESG (Environmental, Social, and Governance) rating for HealthGen. HealthGen's ESG rating was upgraded from "BBB" to "AA", a leading level in the industry. This upgrade reflects not only the recognition of HealthGen's ESG management achievements by the international capital market, but also its affirmation of its long-term sustainable development capabilities.
03
2023-03
What impact and disruption will ChatGPT have on the biopharmaceutical industry? Could the next innovative drug be AI-invented? Recently, following the global popularity of ChatGPT, various industries have begun to pay close attention to the power of technological transformation. The AI concept continues to empower various industries, and the pharmaceutical and medical fields are also being catalyzed by it. In fact, the application of AI in the pharmaceutical and medical fields has gradually transitioned from exploratory practice to commercial transformation. Many companies are already deploying in the AI pharmaceutical field. In the capital market, many institutions have suggested focusing on "AI + medical", "AI + pharmaceutical", and "AI +" opportunities. Hu'an Securities - Pharmaceutical and Biological Research Report points out that AI is a major annual theme, and it is recommended to participate throughout the year, especially companies with landing scenarios and revenue.
05
2025-05
Recently, to boost confidence in the capital market, Chinese regulators have rolled out a series of measures to encourage listed companies to actively return to investors through share buybacks and cash dividends. The China Securities Regulatory Commission (CSRC) has formulated guidelines for market value management and introduced policies encouraging dividends and buybacks, actively promoting a new era of A-share market value management.
04
2025-04
AI Full-Chain Intelligent Upgrade: Health Yuan Starts Efficiency Innovation
In the wave of intelligent transformation of the global pharmaceutical industry, artificial intelligence has become a core force driving the transformation of various industries. The pharmaceutical field is no exception, with AI reshaping the industrial landscape with unprecedented depth and breadth.
04
2025-04
Health Spring: Resilience in Exchange for Elasticity
It's time to test resilience! On one hand, there is downward pressure from the complex market, policy environment, and the transformation of the pharmaceutical industry; on the other hand, there is the upward opportunity of AI technology deeply empowering pharmaceutical companies to accelerate innovation. After a period of collective downturn, Chinese pharmaceutical companies are entering a stage of "structural" differentiation.
04
2025-04
In 2024, how did Health Yuan answer the "three philosophical questions of life"?
In 2024, how did Health Yuan answer the "three philosophical questions of corporate existence"? 2025-04-08 16:23 · Serious Finance Socrates' famous sayings, "Who am I?", "Where do I come from?", "Where am I going?", are three questions about life. For a company, especially a listed company, the questions of corporate existence cannot be avoided: "What kind of company is this?" "Where does the company's money come from?" "Where does the company's money go?"
04
2025-04
On the evening of April 7, Jiankangyuan released its 2024 annual report, showing annual operating revenue of 15.619 billion yuan, net profit attributable to shareholders of 1.387 billion yuan, net profit attributable to shareholders after deducting non-recurring gains and losses of 1.319 billion yuan, and net cash flow from operating activities of 3.636 billion yuan.
04
2025-04
With the increasing number of COPD (Chronic Obstructive Pulmonary Disease) patients globally, existing treatments face the dual challenges of efficacy and compliance. COPD is one of the leading causes of respiratory failure and death worldwide, and while existing treatments have made progress, they still fail to effectively address issues such as acute exacerbations and prolonged disease progression in patients. HealthGen Biotech, through technological innovation, is developing a PREP inhibitor. This breakthrough product will bring new hope to COPD patients while driving progress and development in the global COPD treatment field.
Our Business
Search For The Products You Need
Search For The Products You Need
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.